{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:16:02Z","timestamp":1793711762273,"version":"4.6.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2013,11,23]],"date-time":"2013-11-23T00:00:00Z","timestamp":1385164800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s40265-013-0150-z","type":"journal-article","created":{"date-parts":[[2013,11,22]],"date-time":"2013-11-22T12:56:31Z","timestamp":1385124991000},"page":"2077-2091","source":"Crossref","is-referenced-by-count":53,"title":["Abiraterone Acetate: A Review of Its Use in Patients with Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1007","volume":"73","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,23]]},"reference":[{"issue":"3","key":"150_CR1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/CCO.0b013e32835105b3","volume":"24","author":"EG Bluemn","year":"2012","unstructured":"Bluemn EG, Nelson PS. The androgen\/androgen receptor axis in prostate cancer. Curr Opin Oncol. 2012;24(3):251\u20137.","journal-title":"Curr Opin Oncol"},{"issue":"12","key":"150_CR2","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1158\/1078-0432.CCR-10-2815","volume":"17","author":"C Massard","year":"2011","unstructured":"Massard C, Fizazi K. Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res. 2011;17(12):3876\u201383.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 5","key":"150_CR3","doi-asserted-by":"crossref","first-page":"v129","DOI":"10.1093\/annonc\/mdq174","volume":"21","author":"A Horwich","year":"2010","unstructured":"Horwich A, Parker C, Bangma C, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v129\u201333.","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"150_CR4","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.3747\/co.v17i0.718","volume":"17","author":"SJ Hotte","year":"2010","unstructured":"Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol. 2010;17(Suppl 2):S72\u20139.","journal-title":"Curr Oncol"},{"key":"150_CR5","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer (Version 4.2013). 2013. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf (Accessed 11 Nov 2013)."},{"issue":"18","key":"150_CR6","doi-asserted-by":"crossref","first-page":"5844","DOI":"10.1158\/1078-0432.CCR-11-0644","volume":"17","author":"JL Mohler","year":"2011","unstructured":"Mohler JL, Titus MA, Wilson EM. Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res. 2011;17(18):5844\u20139.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"150_CR7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/1756287212452196","volume":"4","author":"MT Schweizer","year":"2012","unstructured":"Schweizer MT, Antonarakis ES. Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol. 2012;4(4):167\u201378.","journal-title":"Ther Adv Urol"},{"issue":"6","key":"150_CR8","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1200\/JCO.2004.06.037","volume":"22","author":"EJ Small","year":"2004","unstructured":"Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004;22(6):1025\u201333.","journal-title":"J Clin Oncol"},{"issue":"23","key":"150_CR9","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","volume":"27","author":"G Attard","year":"2009","unstructured":"Attard G, Reid AH, A\u2019Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27(23):3742\u20138.","journal-title":"J Clin Oncol"},{"issue":"11","key":"150_CR10","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/j.1464-410X.2012.11445.x","volume":"110","author":"CK Tsao","year":"2012","unstructured":"Tsao CK, Galsky MD, Small AC, et al. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC). BJU Int. 2012;110(11):1580\u20138.","journal-title":"BJU Int"},{"issue":"15","key":"150_CR11","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.2165\/11208080-000000000-00000","volume":"71","author":"LP Yang","year":"2011","unstructured":"Yang LP. Abiraterone acetate: in metastatic castration-resistant prostate cancer [Erratum appears in Drugs. 2012;72(2):192]. Drugs. 2011;71(15):2067\u201377.","journal-title":"Drugs"},{"key":"150_CR12","unstructured":"European Medicines Agency. ZYTIGA 250\u00a0mg tablets: summary of product characteristics; 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002321\/WC500112858.pdf (Accessed 11 Nov 2013)."},{"key":"150_CR13","unstructured":"Janssen Biotech Inc. ZYTIGA\u00ae (abiraterone acetate) tablets: prescribing information; 2013. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/202379s007lbl.pdf (Accessed 11 Nov 2013)."},{"issue":"11","key":"150_CR14","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","volume":"68","author":"RB Montgomery","year":"2008","unstructured":"Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447\u201354.","journal-title":"Cancer Res"},{"issue":"13","key":"150_CR15","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1158\/1078-0432.CCR-12-0908","volume":"18","author":"R Li","year":"2012","unstructured":"Li R, Evaul K, Sharma KK, et al. Abiraterone inhibits 3-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clin Cancer Res. 2012;18(13):3571\u20139.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"150_CR16","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1021\/jm00013a022","volume":"38","author":"GA Potter","year":"1995","unstructured":"Potter GA, Barrie SE, Jarman M, et al. Novel steroidal inhibitors of human cytochrome P45017\u03b1 (17\u03b1-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem. 1995;38(13):2463\u201371.","journal-title":"J Med Chem"},{"issue":"17","key":"150_CR17","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1158\/1078-0432.CCR-10-0255","volume":"16","author":"M Yamaoka","year":"2010","unstructured":"Yamaoka M, Hara T, Kusaka M. Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer. Clin Cancer Res. 2010;16(17):4319\u201324.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"150_CR18","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/sj.bjc.6604904","volume":"100","author":"JE Ang","year":"2009","unstructured":"Ang JE, Olmos D, de Bono JS. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer. 2009;100(5):671\u20135.","journal-title":"Br J Cancer"},{"issue":"28","key":"150_CR19","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","volume":"26","author":"G Attard","year":"2008","unstructured":"Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven [Erratum appears in J Clin Oncol. 2012;30(15):1896]. J Clin Oncol. 2008;26(28):4563\u201371.","journal-title":"J Clin Oncol"},{"issue":"9","key":"150_CR20","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1200\/JCO.2009.24.1281","volume":"28","author":"CJ Ryan","year":"2010","unstructured":"Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010;28(9):1481\u20138.","journal-title":"J Clin Oncol"},{"issue":"6","key":"150_CR21","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1200\/JCO.2010.33.7675","volume":"30","author":"E Efstathiou","year":"2012","unstructured":"Efstathiou E, Titus M, Tsavachidou D, et al. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol. 2012;30(6):637\u201343.","journal-title":"J Clin Oncol"},{"issue":"9","key":"150_CR22","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2009.24.6819","volume":"28","author":"AH Reid","year":"2010","unstructured":"Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010;28(9):1489\u201395.","journal-title":"J Clin Oncol"},{"issue":"9","key":"150_CR23","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1200\/JCO.2009.25.9259","volume":"28","author":"DC Danila","year":"2010","unstructured":"Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010;28(9):1496\u2013501.","journal-title":"J Clin Oncol"},{"issue":"2","key":"150_CR24","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138\u201348.","journal-title":"N Engl J Med"},{"issue":"21","key":"150_CR25","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS Bono de","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995\u20132005.","journal-title":"N Engl J Med"},{"issue":"10","key":"150_CR26","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983\u201392.","journal-title":"Lancet Oncol"},{"issue":"5","key":"150_CR27","doi-asserted-by":"crossref","first-page":"R175","DOI":"10.1530\/ERC-10-0339","volume":"18","author":"C Cai","year":"2011","unstructured":"Cai C, Balk SP. Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer. 2011;18(5):R175\u201382.","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"150_CR28","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1158\/0008-5472.CAN-08-4531","volume":"69","author":"G Attard","year":"2009","unstructured":"Attard G, Reid AH, Olmos D, et al. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res. 2009;69(12):4937\u201340.","journal-title":"Cancer Res"},{"issue":"20","key":"150_CR29","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1158\/0008-5472.CAN-11-0532","volume":"71","author":"C Cai","year":"2011","unstructured":"Cai C, Chen S, Ng P, et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 2011;71(20):6503\u201313.","journal-title":"Cancer Res"},{"issue":"18","key":"150_CR30","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1158\/1078-0432.CCR-11-0728","volume":"17","author":"EA Mostaghel","year":"2011","unstructured":"Mostaghel EA, Marck BT, Plymate SR, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011;17(18):5913\u201325.","journal-title":"Clin Cancer Res"},{"key":"150_CR31","doi-asserted-by":"crossref","unstructured":"van Soest RJ, van Royen ME, de Morr\u00e9e ES, et al. Effects on androgen receptor nuclear import by docetaxel, cabazitaxel, abiraterone, and enzalutamide: potential mechanism for cross-resistance in castration-resistant prostate cancer (CRPC) [abstract no. 5064]. J Clin Oncol. 2013;31(15 Suppl 1).","DOI":"10.1200\/jco.2013.31.15_suppl.5064"},{"issue":"14","key":"150_CR32","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1158\/1078-0432.CCR-11-0815","volume":"17","author":"CJ Ryan","year":"2011","unstructured":"Ryan CJ, Shah S, Efstathiou E, et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011;17(14):4854\u201361.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"150_CR33","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00280-012-1916-9","volume":"70","author":"AW Tolcher","year":"2012","unstructured":"Tolcher AW, Chi KN, Shore ND, et al. Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2012;70(2):305\u201313.","journal-title":"Cancer Chemother Pharmacol"},{"key":"150_CR34","doi-asserted-by":"crossref","first-page":"S501","DOI":"10.1016\/S0959-8049(11)72006-8","volume":"47","author":"T Marbury","year":"2011","unstructured":"Marbury T, Stonerock R, Acharya M, et al. A phase 1 single-dose open-label pharmacokinetic (PK) study of abiraterone acetate (AA) in male subjects with mild or moderate hepatic impairment [abstract no. 7055]. Eur J Cancer. 2011;47:S501.","journal-title":"Eur J Cancer"},{"key":"150_CR35","doi-asserted-by":"crossref","first-page":"S502","DOI":"10.1016\/S0959-8049(11)72008-1","volume":"47","author":"T Marbury","year":"2011","unstructured":"Marbury T, Stonerock R, Tran N, et al. A phase 1 single dose open-label reduced\/staged pharmacokinetic (PK) and safety study of abiraterone acetate (AA) in men with impaired renal function [abstract no. 7057]. Eur J Cancer. 2011;47:S502.","journal-title":"Eur J Cancer"},{"issue":"1","key":"150_CR36","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00280-012-2001-0","volume":"71","author":"KN Chi","year":"2013","unstructured":"Chi KN, Tolcher A, Lee P, et al. Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2013;71(1):237\u201344.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"150_CR37","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S1470-2045(12)70473-4","volume":"13","author":"CJ Logothetis","year":"2012","unstructured":"Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012;13(12):1210\u20137.","journal-title":"Lancet Oncol"},{"issue":"4","key":"150_CR38","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/annonc\/mds585","volume":"24","author":"CN Sternberg","year":"2013","unstructured":"Sternberg CN, Molina A, North S, et al. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Ann Oncol. 2013;24(4):1017\u201325.","journal-title":"Ann Oncol"},{"key":"150_CR39","doi-asserted-by":"crossref","unstructured":"Harland S, Staffurth J, Molina A, et al. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer 2013;49(17):3648\u201357.","DOI":"10.1016\/j.ejca.2013.07.144"},{"issue":"4 Suppl","key":"150_CR40","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/j.juro.2013.02.272","volume":"189","author":"F Saad","year":"2013","unstructured":"Saad F, Shore ND, Van Poppel H, et al. Abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy: interim analysis of the COU-AA-302 phase 3 trial [abstract no. 713]. J Urol. 2013;189(4 Suppl):e293.","journal-title":"J Urol"},{"issue":"4 Suppl","key":"150_CR41","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1016\/j.juro.2013.02.348","volume":"189","author":"N Shore","year":"2013","unstructured":"Shore N, Ryan CJ, Mulders P, et al. The impact of abiraterone acetate therapy on patient-reported pain and functional status in chemotherapy-na\u00efve patients with progressive, metastatic castration-resistant prostate cancer: results from an updated analysis [abstract no. 784]. J Urol. 2013;189(4 Suppl):e323.","journal-title":"J Urol"},{"key":"150_CR42","doi-asserted-by":"crossref","unstructured":"Scher HI, Heller G, Molina A, et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel [abstract no. LBA4517]. J Clin Oncol. 2011;29(18 Suppl 2).","DOI":"10.1200\/jco.2011.29.18_suppl.lba4517"},{"key":"150_CR43","doi-asserted-by":"crossref","unstructured":"Goodman OB, Flaig TW, Molina A, et al. Exploratory analysis of the visceral disease (VD) patient subset in COU-AA-301, a phase III study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) [abstract no. 14]. J Clin Oncol. 2013;31(Suppl 6).","DOI":"10.1200\/jco.2013.31.6_suppl.14"},{"key":"150_CR44","unstructured":"European Medicines Agency. Assessment report: Zytiga (abiraterone); 2012. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/002321\/WC500137814.pdf (Accessed 11 Nov 2013)."},{"key":"150_CR45","doi-asserted-by":"crossref","unstructured":"Rathkopf DE, Smith MR, de Bono JS, et al. Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302) [abstract no. 5009]. J Clin Oncol. 2013;31(15 Suppl 1).","DOI":"10.1200\/jco.2013.31.15_suppl.5009"},{"key":"150_CR46","unstructured":"Heidenreich A, Bolla M, Joniau S, et al. Guidelines on prostate cancer; 2011. http:\/\/www.uroweb.org\/gls\/pdf\/08_Prostate_Cancer.pdf (Accessed 11 Nov 2013)."},{"key":"150_CR47","unstructured":"European Medicines Agency. Xtandi 40\u00a0mg soft capsules: summary of product characteristics; 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002639\/WC500144996.pdf (Accessed 11 Nov 2013)."},{"key":"150_CR48","unstructured":"Astellas Pharma US Inc. XTANDI\u00ae (enzalutamide) capsules for oral use: prescribing information; 2012. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203415lbl.pdf (Accessed 11 Nov 2013)."},{"issue":"13","key":"150_CR49","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187\u201397.","journal-title":"N Engl J Med"},{"issue":"13","key":"150_CR50","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.2174\/138945012803529956","volume":"13","author":"P Rescigno","year":"2012","unstructured":"Rescigno P, Buonerba C, Bellmunt J, et al. New perspectives in the therapy of castration resistant prostate cancer. Curr Drug Targets. 2012;13(13):1676\u201386.","journal-title":"Curr Drug Targets"},{"issue":"1","key":"150_CR51","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/11206840-000000000-00000","volume":"71","author":"GL Plosker","year":"2011","unstructured":"Plosker GL. Sipuleucel-T: in metastatic castration-resistant prostate cancer. Drugs. 2011;71(1):101\u20138.","journal-title":"Drugs"},{"issue":"4","key":"150_CR52","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.eururo.2011.01.025","volume":"59","author":"N Mottet","year":"2011","unstructured":"Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59(4):572\u201383.","journal-title":"Eur Urol"},{"issue":"11","key":"150_CR53","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.2165\/11209660-000000000-00000","volume":"72","author":"K McKeage","year":"2012","unstructured":"McKeage K. Docetaxel: a review of its use for the first-line treatment of advanced castration-resistant prostate cancer. Drugs. 2012;72(11):1559\u201377.","journal-title":"Drugs"},{"issue":"5","key":"150_CR54","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40266-013-0078-8","volume":"30","author":"GM Keating","year":"2013","unstructured":"Keating GM. Cabazitaxel: a guide to its use in hormone-refractory metastatic prostate cancer. Drugs Aging. 2013;30(5):359\u201365.","journal-title":"Drugs Aging"},{"key":"150_CR55","unstructured":"National Institute for Health and Clinical Excellence. Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (NICE technology appraisal guidance 259); 2012. http:\/\/guidance.nice.org.uk\/TA259\/Guidance\/pdf\/English (Accessed 11 Nov 2013)."},{"issue":"7","key":"150_CR56","doi-asserted-by":"crossref","first-page":"A424","DOI":"10.1016\/j.jval.2012.08.2126","volume":"15","author":"ML Pereira","year":"2012","unstructured":"Pereira ML, Bahmdouni LS, Pepe C, et al. Cost-effectiveness analysis of abiraterone for the treatment of advanced prostate cancer under the Brazilian private health care system [abstract no. PCN86]. Value Health. 2012;15(7):A424\u20135.","journal-title":"Value Health"},{"issue":"4","key":"150_CR57","doi-asserted-by":"crossref","first-page":"A219","DOI":"10.1016\/j.jval.2012.03.1183","volume":"15","author":"U Persson","year":"2012","unstructured":"Persson U, Nilsson S, Hjortsberg C, et al. Economic evaluation of abiraterone acetate as treatment for metastatic castration resistant prostate cancer after failure of docetaxel in Sweden [abstract no. PCN66]. Value Health. 2012;15(4):A219.","journal-title":"Value Health"},{"issue":"4","key":"150_CR58","doi-asserted-by":"crossref","first-page":"A220","DOI":"10.1016\/j.jval.2012.03.1189","volume":"15","author":"LS Wilson","year":"2012","unstructured":"Wilson LS, Zhong L, Pon V, et al. Cost effectiveness analysis of new treatments for metastatic castration-resistant prostate cancer: does severity matter? [abstract no. PCN72]. Value Health. 2012;15(4):A220\u20131.","journal-title":"Value Health"},{"issue":"7","key":"150_CR59","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148\u201359.","journal-title":"J Clin Oncol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0150-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0150-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0150-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T03:25:21Z","timestamp":1647487521000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0150-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,23]]},"references-count":59,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["150"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0150-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,23]]}}}